Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK

ConclusionIntravitreal ranibizumab is a highly cost-effective intervention for the treatment of CNV due to causes other than nAMD and PM as it delivers substantial QALY gains to patients while making cost savings vs. BSC.FundingNovartis Pharmaceuticals UK Ltd.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research